FDA approves new indication for MSD’s Zerbaxa
pharmafile | June 5, 2019 | News story | Research and Development | Merck, Zerbaxa, bacterial infection, pharma
The FDA has approved US firm Merck’s Zerbaxa (ceftolozane and tazobactam) for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
The new indication comes after MSD’s drug was first approved for treating complicated intra-abdominal infections and urinary tract infections by the FDA in 2014.
The drug showed similar efficacy to another antibacterial drug in a clinical trial of 726 patients who had been hospitalised with HABP/VABP.
Elevated liver enzyme levels, renal impairment or failure, and diarrhea were amongst the most commonly reported adverse reactions.
Louis Goss
Related Content
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
Merck, known as MSD outside of the US and Canada, has announced that the US …
Merck to acquire EyeBio for an upfront $1.3bn
Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
Merck, known as MSD outside of the US and Canada, has announced results from the …